10Laboratory and Blood Work-up

FWhy most patients need no bloods at all

Tinnitus is overwhelmingly an auditory-system phenomenon, and in the typical patient — gradual onset, bilateral, with a matching high-frequency hearing loss — no blood test changes management. Guideline groups are explicit that routine laboratory screening is not recommended for the unselected tinnitus patient [2014]. A “tinnitus panel” ordered on every comer mostly generates incidental abnormalities, patient anxiety and cost without yield.

The value of bloods appears only when the history flags a systemic contributor: fatigue and pallor, weight or temperature intolerance, polyuria, neuropathy, an inflammatory arthropathy, or rapidly progressive or fluctuating hearing loss. In those patients a targeted test is high-yield. The governing principle for this whole module is the same as for imaging: test by clinical suspicion, not by protocol.

TThe targeted panel and what each test is asking

When a systemic driver is suspected, build the request from the symptoms rather than a fixed bundle. A full blood count looks for anaemia, which is associated with new-onset tinnitus — a recent cohort found iron-deficiency anaemia raised the risk of new-onset tinnitus, particularly in women [2025]. Thyroid function is checked when there are symptoms of hypo- or hyperthyroidism; both ends of thyroid dysfunction are linked to inner-ear and cochleo-vestibular symptoms [2025].

Fasting glucose or HbA1c is reasonable where diabetes is suspected or unscreened, given a meta-analytic association between diabetes mellitus and tinnitus [2025]. A lipid profile may be added when vascular risk is being assessed. B12 and folate are checked with neuropathy, glossitis or a vegetarian/elderly context; ESR/CRP with an autoimmune screen (ANA, RF) belongs to suspected autoimmune inner-ear disease or systemic inflammatory disease; renal function and LFTs matter mainly to interpret or monitor ototoxic drugs.

CAutoimmune inner-ear disease — the time-critical pattern

One laboratory pathway is genuinely urgent. Rapidly progressive, often fluctuating, frequently bilateral sensorineural hearing loss with tinnitus over weeks should raise autoimmune inner-ear disease (AIED). Here ESR, CRP and an autoimmune screen are ordered not to confirm a diagnosis — AIED remains clinical and steroid-responsive — but to detect a treatable systemic vasculitis or connective-tissue disease and to support early immunosuppression. Delay costs hearing.

Contrast this with the patient who has stable, bilateral, age-appropriate tinnitus: no autoimmune work-up is indicated. The lesson is that the tempo and pattern of the hearing loss, not the tinnitus itself, drive the decision to send inflammatory markers.

CReading the results without over-reacting

A targeted, abnormal result is only useful if you correct the abnormality and then re-assess the tinnitus. Treating iron-deficiency anaemia, restoring euthyroidism, optimising glycaemia or replacing B12 can each modestly improve the symptom — but the association is rarely one-to-one, and counselling should set realistic expectations [2013]. Equally important is resisting the temptation to chase a borderline incidental finding that has no plausible link to the patient’s presentation.

Document the indication beside each test you order. If you cannot state in one line why a given test might change management, that is the signal not to send it.